Profil
Calvin Yu worked as Senior Director-Finance & SEC Reporting at Adverum Biotechnologies, Inc. from 2014 to 2016.
Prior to that, he worked as Controller at Five Prime Therapeutics, Inc. from 2010 to 2014.
He also worked as Controller at Stemcentrx, Inc. from 2016 to 2017.
Currently, he is the Chief Financial & Accounting Officer at Alector, Inc. Mr. Yu completed his undergraduate degree from San Francisco State University.
Anciens postes connus de Calvin Yu
| Sociétés | Poste | Fin |
|---|---|---|
Stemcentrx, Inc.
 Stemcentrx, Inc. BiotechnologyHealth Technology Stemcentrx, Inc. develops life-changing therapies for cancer patients. It develops proprietary discovery platforms that yield unprecedented insight into the biology of tumors and are being exploited to develop potent new cancer drugs. The firm specializes in designing drugs to target cancer stem cells, which are the cells that cause cancer to spread throughout the body. The company was founded by Brian Christopher Slingerland, Daniel T. Reiner and Scott J. Dylla in 2008 and is headquartered in San Francisco, CA. | Comptroller/Controller/Auditor | 01/06/2017 |
| ADVERUM BIOTECHNOLOGIES, INC. | Director of Finance/CFO | 01/02/2016 |
| FIVE PRIME THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/09/2014 |
| ALECTOR, INC. | Director of Finance/CFO | 08/09/2021 |
Formation de Calvin Yu
| San Francisco State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| ALECTOR, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Stemcentrx, Inc.
Stemcentrx, Inc. BiotechnologyHealth Technology Stemcentrx, Inc. develops life-changing therapies for cancer patients. It develops proprietary discovery platforms that yield unprecedented insight into the biology of tumors and are being exploited to develop potent new cancer drugs. The firm specializes in designing drugs to target cancer stem cells, which are the cells that cause cancer to spread throughout the body. The company was founded by Brian Christopher Slingerland, Daniel T. Reiner and Scott J. Dylla in 2008 and is headquartered in San Francisco, CA. | Health Technology |
